首批药品集采品种采购量变化的影响因素分析

刘雨欣; 文小桐; 段凤然; 王越; 杨莹; 毛宗福

doi:10.6039/j.issn.1001-0408.2024.06.01

您当前的位置：

首页 >

文章列表页 >

首批药品集采品种采购量变化的影响因素分析

药事管理 | 更新时间：2024-04-09

- 首批药品集采品种采购量变化的影响因素分析
- Analysis of influential factors for purchasing quantity changes in the procurement varieties of the first batch of drug centralized procurement
- 中国药房 2024年35卷第6期页码：641-646
- 作者机构：
  
  1.武汉大学董辅礽经济社会发展研究院，武汉　430071
  2.武汉大学全球健康研究中心，武汉　430071
  3.武汉大学公共卫生学院，武汉　430071
  4.华中科技大学同济医学院护理学院，武汉　430030
- 作者简介：
  
  硕士研究生。研究方向：医保政策、健康经济。 E-mail：yuxin__work103@163.com
  教授，博士生导师，博士。研究方向：卫生政策与卫生评价。E-mail：zfmao@whu.edu.cn
- 基金信息：
  
  国家卫生健康委体制改革司委托项目
- DOI：10.6039/j.issn.1001-0408.2024.06.01
  中图分类号： R95
- 纸质出版日期：2024-03-30，
  
  收稿日期：2023-06-17，
  
  修回日期：2024-03-04，
扫描看全文
刘雨欣,文小桐,段凤然等.首批药品集采品种采购量变化的影响因素分析 ^Δ[J].中国药房,2024,35(06):641-646.

LIU Yuxin,WEN Xiaotong,DUAN Fengran,et al.Analysis of influential factors for purchasing quantity changes in the procurement varieties of the first batch of drug centralized procurement[J].ZHONGGUO YAOFANG,2024,35(06):641-646.
刘雨欣,文小桐,段凤然等.首批药品集采品种采购量变化的影响因素分析 ^Δ[J].中国药房,2024,35(06):641-646. DOI： 10.6039/j.issn.1001-0408.2024.06.01.

LIU Yuxin,WEN Xiaotong,DUAN Fengran,et al.Analysis of influential factors for purchasing quantity changes in the procurement varieties of the first batch of drug centralized procurement[J].ZHONGGUO YAOFANG,2024,35(06):641-646. DOI： 10.6039/j.issn.1001-0408.2024.06.01.

摘要

目的

探讨首批药品集中带量采购（简称“集采”）品种采购量变化的影响因素。

方法

选取“4+7”政策的25个集采品种为研究对象，对“4+7”试点、续约、扩围政策实施前后上述集采品种的采购量变化进行分析，并从药品、医疗机构、地区3个层面确定影响因素，采用多元线性回归模型分析集采品种采购量变化的影响因素。

结果

“4+7”试点、续约、扩围政策干预期的采购量较基期平均分别增长52.1万DDDs、－0.2万DDDs、85.8万DDDs。在试点、续约、扩围期，集采品种的DDDc降幅都与集采品种的采购量增量呈显著正相关（

＜0.01）。在试点和续约期，完全可替代药品品种数与集采品种的采购量增量呈显著正相关（

＜0.1）；在试点和扩围期，一定程度可替代药品品种数与集采品种的采购量增量呈显著负相关（

＜0.05）。在续约期，三级医院集采品种的采购量增量显著小于基层医疗机构（

＜0.05）。

结论

集采品种采购量的变化幅度与DDDc降幅相关，集采后药品价格降幅越大，其采购量的增幅就越大；集采品种的可替代药品品种数对其采购量变化有影响，但不稳定；随着政策实施，基层医疗机构的“放量”效果逐渐超过三级医院，提示集采品种的用量在向基层医疗机构转移，集采政策推动了分级诊疗制度的实施。

Abstract

OBJECTIVE

To investigate the factors influencing the changes in purchasing quantity in the procurement varieties of the first batch of volume-based drug centralized procurement （hereinafter referred to as centralized procurement）.

METHODS

Using 25 procurement varieties of the “4+7” policy as research objects， the changes in purchasing quantity of procurement varieties were analyzed before and after the implementation of the “4+7” pilot， renewal and expansion policies. The influential factors were determined from the three levels of drugs， medical institutions and regions； and the multiple linear regression model was used to analyze the influential factors for the changes in the purchasing quantity of procurement varieties.

RESULTS

Before and after the implementation of the “4+7” pilot， renewal and expansion policies， the purchasing quantity increased by 52.1，－0.2， 85.8 ten thousand DDDs on average， compared with base period. During pilot， renewal and expansion period， DDDc decrease in procurement varieties was positively correlated with the increase in purchasing quantity （

＜0.01）. During the pilot and renewal period， the number of absolutely alternative varieties was positively correlated with the increase in purchasing quantity （

＜0.1）. During the pilot and expansion period， the number of alternative varieties to a certain extent was negatively correlated with the increase in purchasing quantity （

＜0.05）. During the renewal period， the increment of purchasing quantity in tertiary hospitals was smaller than that of primary medical institutions （

＜0.05）.

CONCLUSIONS

There is a relationship between the decline of DDDc and the changes in the purchasing quantity， that is， the more the drug price dropped， the more the purchasing quantity increased. The number of alternative varieties for centralized procurement will affect the changes in their purchasing quantity， but it is not always stable. With the implementation of the policy， the volume of primary medical institutions gradually exceeds that of tertiary institutions， indicating that the consumption of centralized purchased varieties is transferred to the primary medical institutions， and centralized procurement has promoted the implementation of the hierarchical diagnosis and treatment system.

关键词

药品集中带量采购采购量影响因素

Keywords

volume-based centralized procurementpurchasing quantityinfluential factors

references

SEIDMAN G，ATUN R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals，vaccines or health pro-ducts? A systematic review of evidence from low-income and middle-income countries[J]. BMJ Glob Health，2017，2（2）：e000243.

YANG Y，CHEN L，KE X F，et al. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen，2018-2019：an interrupted time-series analysis[J]. BMC Health Serv Res，2021，21（1）：668.

YANG Y，TONG R W，YIN S C，et al. The impact of “4 + 7” volume-based drug procurement on the volume，expenditures，and daily costs of antihypertensive drugs in Shenzhen，China：an interrupted time series analysis[J]. BMC Health Serv Res，2021，21（1）：1275.

闫娟娟，赵耀伟，闫彬，等. 基于间断时间序列的药品带量采购政策实施效果研究[J]. 价格理论与实践，2022（12）：56-60，195.

YAN J J，ZHAO Y W，YAN B，et al. Study on the implementation effect of drug purchase policy based on discontinuous time series[J]. Price Theory Pract，2022（12）：56-60，195.

陈缪丰，谢金平，王斌，等. 常州市各级医院带量采购政策实施效果差异研究[J]. 中国卫生资源，2022，25（6）：765-769，779.

CHEN M F，XIE J P，WANG B，et al. Study on the dif-ference of implementation effect of purchasing policy with quantity in hospitals at all levels in Changzhou[J]. Chin Health Resour，2022，25（6）：765-769，779.

徐源，宋捷，陈珉惺. 上海医疗保险药品带量采购的政策效果及启示[J]. 中国卫生资源，2022，25（3）：278-282.

XU Y，SONG J，CHEN M X. Policy effect and enlightenment of Shanghai medical insurance drug purchase with quantity[J]. Chin Health Resour，2022，25（3）：278-282.

文小桐，王越，段凤然，等. 集采政策对不同等级公立医疗机构药品采购的影响[J]. 中国医疗保险，2023（3）：32-40.

WEN X T，WANG Y，DUAN F R，et al. The impact of national centralized drug procurement on the drug procurement in different levels of public medical institutions[J]. China Health Insur，2023（3）：32-40.

艾美达医药咨询. 第一至五批国采品种可替代药品目录发布[EB/OL].（2021-12-17）[2023-06-22].https：//xueqiu.com/9517383519/206283730https://xueqiu.com/9517383519/206283730.

Aimeda Medical Consulting. The first to fifth batches of substitute drugs for domestically purchased varieties have been released[EB/OL].（2021-12-12）[2023-06-22].https：//xueqiu.com/9517383519/206283730https://xueqiu.com/9517383519/206283730.

姜姗，葛卫红，穆耕林，等. 国家组织药品集中带量采购在某公立医院的实施效果分析[J]. 中国医院管理，2022，42（7）：70-73.

JIANG S，GE W H，MU G L，et al. Analysis of the implementation effect of the national volume-based procurement in a public hospital[J]. Chin Hosp Manag，2022，42（7）：70-73.

赵洁，李巍，王皋俊. 价值医疗视角下国家药品集中带量采购在某公立医院的实施效果评价[J]. 中国药房，2021，32（19）：2410-2414.

ZHAO J，LI W，WANG G J. Effect evaluation of national drug centralized volume-based procurement in a public hospital from the perspective of value-based healthcare[J]. China Pharm，2021，32（19）：2410-2414.

杨智芳，杨林，邱磊，等. 国家药品带量采购在上海市松江区某二级医院执行效果分析[J]. 中国处方药，2022，20（6）：32-35.

YANG Z F，YANG L，QIU L，et al. Effect analysis of national drug procurement with quantity in a secondary hospital in Songjiang district of Shanghai[J]. J China Prescr Drug，2022，20（6）：32-35.

李春秀，杨志勇，刘翌，等. “4+7” 带量采购政策下成都大学附属医院调血脂药使用情况分析[J]. 现代药物与临床，2022，37（1）：179-186.

LI C X，YANG Z Y，LIU Y，et al. Utilization analysis of “4+7” procurement policy with quantity on using of lipid-regulating drugs in the Affiliated Hospital of Chengdu University[J]. Drugs Clin，2022，37（1）：179-186.

梁灿强. 比较价格法和反垄断法对药品需求价格弹性的影响[J]. 法制与社会，2009（29）：137-138.

LIANG C Q. Compare the influence of price law and anti-monopoly law on the price elasticity of drug demand[J]. Leg Syst Soc，2009（29）：137-138.

HURSH S R. Behavioral economics of drug self-administration：an introduction[J]. Drug Alcohol Depend，1993，33（2）：165-172.

高锦娟，吴秀芳，许云，等. 药品集中带量采购对某院高血压相关药品价格指数的影响[J]. 海峡药学，2021，33（7）：214-217.

GAO J J，WU X F，XU Y，et al. Influence of centralized drug purchase on the price index of hypertension-related drugs in a hospital[J]. Strait Pharm J，2021，33（7）：214-217.

文小桐，赵秋玲，刘雨欣，等.不同等级医疗机构对集采药品采购量变化的贡献率差异比较[J].中国医疗保险，2023（11）：122-128.

WEN X T，ZHAO Q L，LIU Y X，et al. Comparison of the contribution rate of different levels of public medical institutions to the changes in centralized drug procurement vo-lume[J].China Health Insur，2023（11）：122-128.

毛振华.中国互联网医疗发展报告：2022－2023：医疗健康大数据[M].北京：社会科学文献出版社，2023：67-85.

MAO Z H. China internet medical development report：2022-2023：medical and health big data[M].Beijing：Social Science Academic Press，2023：67-85.

孙言，朱正，杨莉. 国家组织药品集中带量采购价格降幅影响因素分析[J]. 中国卫生政策研究，2022，15（2）：54-59.

SUN Y，ZHU Z，YANG L. Analysis on influencing factors of price reduction in national volume-based drug procurement[J]. Chin J Health Policy，2022，15（2）：54-59.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

山西省医院骨科手术患者药品费用的特征与影响因素研究

糖尿病患者DRG分组效果及住院费用影响因素分析

贵州省老年结核病患者多重用药负担及影响因素分析

替加环素治疗多重耐药鲍曼不动杆菌肺炎失败的影响因素分析

我国省级基本药物增补情况与影响因素分析